SGSarah Camille Glover

Sarah Camille Glover

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sarah Camille Glover has a total of 531 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Li

    Division of Gastroenterology, Department of Medicine, University of Florida, Gainesville, Fla

    13 shared publications
  • Tanya O. Robinson

    Division of Digestive Diseases, Department of Medicine, University of Mississippi Medical Center

    11 shared publications
  • Richard V. Benya

    Department of Medicine, University of Illinois at Chicago and Chicago Veterans Administration Medical Center (West Side Division), Chicago, Illinois; Department of Mechanical and Aerospace Engineering, University of Florida, Gainesville, Florida; and Department of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois

    10 shared publications
  • Anna H. Owings

    Division of Digestive Diseases, Department of Medicine, University of Mississippi Medical Center

    9 shared publications
  • Hannah Laird

    Department of Medicine University of Mississippi Medical Center Jackson Mississippi USA

    9 shared publications
  • Bruce H. Horwitz

    Boston Children's Hospital

    7 shared publications

Latest Publications

  • Open Access

    Long-term Benefits of Mirikizumab on Patient-Reported Outcomes in Individuals with Crohn's Disease: 2-Year Results from the VIVID-2 Extension Study

    by Minhu Chen, Ailsa Hart, Aisha Vadhariya, Yiying Brogan, Wai Man Maria Chan, Richard E. Moses, Na Lu, Ashwin Ananthakrishnan, Sarah C Glover, Millie Long, et al.

    Background: Mirikizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated clinical efficacy in Crohn’s disease (CD), improving symptoms and quality of life (QoL) over one year in the VIVID-1 trial. This analysis from the VIVID-2 open-label extension evaluated its long-term impact on CD symptoms and QoL at two years. Methods: Patients from VIVID-1 with an endoscopic response continued mirikizumab (300 mg subcutaneous) in VIVID-2. Endoscopic non-responders at 52 weeks underwent re-induction, then maintenance therapy. QoL was assessed at Weeks 64 and/or 104 using the Inflammatory Bowel Disease Questionnaire (IBDQ), EQ-5D-5L visual analog scale (VAS), and work productivity by Work Productivity and Activity Impairment: Crohn’s Disease (WPAI:CD) questionnaire. Other patient-reported outcomes (PRO) assessed were fatigue (FACIT-Fatigue), abdominal pain (AP), stool frequency (SF), and clinical remission by PRO (AP ≤1 and SF ≤3, no worsening from baseline). Missing data were handled with modified non-responder imputation for categorical outcomes, and baseline observation carried forward for continuous outcomes. Analysis of covariance was used to estimate mean changes from baseline. Results: At 104 weeks, 85.0% of VIVID-1 endoscopic responders and 72.6% endoscopic non-responders achieved IBDQ response, while 71.3% endoscopic responders and 60.8% endoscopic non-responders achieved IBDQ remission. By Week 64, EQ-5D-5L VAS scores improved by 22–27 points, WPAI decreased by 14–34 points, and >60% patients achieved meaningful improvement in fatigue. Approximately 75% responders and 54% non-responders achieved clinical remission by PRO at two years. Conclusion: Long-term mirikizumab treatment led to sustained QoL improvements and reduced symptoms in patients with CD, regardless of their endoscopic response status.

  • Open Access

    Hereditary α-tryptasemia; a review of mechanisms linking α-tryptase gene dosage to intestinal homeostasis and immunopathology

    by Ilaria M. Simeone, Michelle Galeas-Pena, Katelyn White, Brandy Sullivan, Alexandra Morelli, Jocelyn A. Silvester, Liza Konnikova, Amelie Therrien, Sarah C. Glover

    Hereditary α-tryptasemia (HαT) is a genetic trait characterized by increased TPSAB1 copy number. Identified in 2015, the HαT trait impacts approximately 4%–6% of individuals of European ancestry and manifests with core clinical features in one-third of individuals who test positive for the genetic trait. HαT represents a natural human model of α-tryptase overexpression which can be leveraged to better and more comprehensively understand tryptase and mast cell (MC) biology at the tissue level. In this review, we synthesize emerging evidence demonstrating that HαT is a clinically significant modifier of disease in the gastrointestinal (GI) tract. We summarize findings demonstrating that HαT impacts small intestinal immunopathology even in the absence of overt GI pathology. In celiac disease, coexisting HαT is associated with increased duodenal MCs and persistent GI symptoms (diarrhea, bloating, abdominal pain) despite a gluten-free diet. We also review emerging data indicating that HαT may act as a disease modifier in inflammatory bowel disease (IBD); increased α-tryptase gene dosage is associated with intestinal MC activation and increased expression of MRGPRX2. These changes may amplify MC–mediated inflammatory pathways within the intestinal mucosa and contribute to the complexity of immune signaling traditionally attributed to T-cell–driven inflammation in IBD. Taken together, emerging modern cellular and molecular biology evidence suggests that the natural overexpression of α-tryptase in HαT alters MC behavior and GI intestinal immunopathology, thereby modifying disease outcomes across a spectrum of GI illnesses.

  • Open Access

    Virion-Independent Extracellular Vesicle (EV)-Dependent Transmission of SARS-CoV-2 as a Potential New Mechanism of Viral RNA Spread in Human Cells

    by Nergiz Ekmen, Ali Riza Koksal, Dong Lin, Di Tian, Paul Thevenot, Sarah Glover, Srikanta Dash

    The concentration of extracellular vesicles (EVs) in the peripheral blood of COVID-19 patients is increased. Nevertheless, their potential role in the transmission of infection remains unclear. This study was performed to determine whether EVs produced by the sub-genomic replicon system developed in Baby Hamster Kidney (BHK-21) cells could transfer SARS-CoV-2 replicon RNA, leading to the establishment of a viral replication system in human cells. Purified EVs from the SARS-CoV-2 sub-genomic replicon cell line BHK-21 were cultured with a naive human cell line. The success of EV-mediated transfer of SARS-CoV-2 replicon RNA and its productive replication was assessed using G-418 selection, a luciferase assay, immunostaining, and Western blot. We found that the A549 cell line cultured with EVs isolated from SARS-CoV-2 BHK-21 replicon cells developed G-418-resistant cell colonies. SARS-COV-2 RNA replication in A549 cells was confirmed by nano luciferase, Nsp1 protein. SARS-CoV-2 RNA replication causes massive morphological changes. Treatment of cells with the FDA-approved Paxlovid demonstrated a dose-dependent inhibition of viral replication. We isolated two human epithelial cell lines (gastrointestinal and neuroblastoma) and one vascular endothelial cell line that stably support high-level replication of SARS-CoV-2 sub-genomic RNA. Viral elimination did not revert the abnormal cellular shape, vesicle accumulation, syncytia formation, or EV release. Our study’s findings highlight the potential implications of EV-mediated transfer of replicon RNA to permissive cells. The replicon model is a valuable tool for studying virus-induced reversible and irreversible cellular reprogramming, as well as for testing novel therapeutic strategies for SARS-CoV-2.

  • Open Access

    MRGPRX2-expressing mast cells are increased in the GI tract of individuals with active inflammatory bowel disease and hereditary α-tryptasemia

    by Michelle Galeas-Pena, Jonathan J. Lyons, Dhana Llivichuzhca-Loja, Steve Everman, Ghina Yaghi, Katelyn White, Sangita Sutradhar, Tanya O. Robinson, Anna H. Owings, Neha S. Dhaliwal, et al.

    Introduction: Hereditary α-tryptasemia (HαT), defined by increased TPSAB1 copy number and elevated basal serum tryptase, is associated with mast cell (MC)–mediated symptoms. However, its role in gastrointestinal disease remains unclear. Because intestinal MCs express the non–IgE-dependent activation receptor MRGPRX2, we investigated whether MRGPRX2 expression and MC phenotypes are altered in individuals with HαT in the context of inflammatory bowel disease (IBD). Methods: We genotyped 854 biobanked IBD samples to identify individuals with HαT. Spatial transcriptomic analysis was performed on descending colon tissue from individuals with HαT ( n = 4) as well as tissue and severity matched non-HαT controls ( n = 4). Small intestinal biopsies were additionally analyzed using mass cytometry (CyTOF) from HαT individuals ( n = 5) and non-HαT controls ( n = 9). Droplet digital PCR (ddPCR) was used to establish TPSAB1 copy number variant for HαT detection. Comparisons across groups were performed using Welch's t -test with effect sizes and 95% CI. Results: Across complementary platforms, HαT was associated with increased gastrointestinal mast cell abundance and elevated expression of mast cell activation markers, including CD203c, LAMP-1, and SIGLEC8. Both spatial transcriptomics and ddPCR demonstrated significantly increased MRGPRX2 and SIGLEC8 transcript levels in IBD samples from individuals with HαT compared with matched non-HαT IBD controls. Discussion: These findings suggest that enhanced MRGPRX2 expression and mast cell activation may contribute to gastrointestinal symptoms in individuals with HαT, particularly in the setting of IBD. As interest in precision immunogenetics grows, defining mast cell phenotypes linked to α-tryptase copy number may help refine diagnostic evaluation and identify patients who could benefit from emerging mast cell–targeted therapeutic strategies in the context of IBD.


  • Open Access

    MRGPRX2-expressing mast cells are increased in the GI tract of individuals with active inflammatory bowel disease and hereditary α-tryptasemia

    by Michelle Galeas-Pena, Jonathan J. Lyons, Dhana Llivichuzhca-Loja, Steve Everman, Ghina Yaghi, Katelyn White, Sangita Sutradhar, Tanya O. Robinson, Anna H. Owings, Neha S. Dhaliwal, et al.

    Hereditary α-tryptasemia (HαT), defined by increased TPSAB1 copy number and elevated basal serum tryptase, is associated with mast cell (MC)–mediated symptoms, yet its role in gastrointestinal disease remains unclear. Because intestinal MCs express the non-IgE–dependent activation receptor MRGPRX2, we investigated whether MRGPRX2 expression is altered in individuals with HαT and inflammatory bowel disease (IBD). We genotyped 854 biobanked IBD samples, performed spatial transcriptomics on descending colon tissue (n = 4 HαT; n = 4 non-HαT), and analyzed small-intestinal biopsies by mass cytometry (CyTOF; n = 5 HαT; n = 9 controls). Across these complementary platforms, HαT was associated with increased gastrointestinal MC abundance and higher expression of activation markers including CD203c, LAMP-1, and SIGLEC8. Both spatial transcriptomics and ddPCR demonstrated significantly increased MRGPRX2 and SIGLEC8 transcripts in IBD samples from individuals with HαT compared with matched non-HαT IBD cases. These findings suggest that enhanced MRGPRX2 expression and associated MC activation may contribute to gastrointestinal symptoms in HαT, particularly in the context of IBD. As interest in precision immunogenetics grows, defining MC phenotypes linked to α-tryptase copy number may help refine diagnostic evaluation and identify patients who could benefit from emerging mast cell–targeted therapeutic strategies in the context of IBD.

  • Hereditary Alpha-Tryptasemia Is Associated With Ongoing Symptoms in Individuals With Celiac Disease Despite Following a Gluten-free Diet

    by Amelie Therrien, Srihitha Akula, Michelle Galeas-Pena, Emma Frank, Lily Gillette, Jocelyn A. Silvester, Daniel A. Leffler, Javier Villafuerte Galvez, Ciaran P. Kelly, Olga Pozdnyakova, et al.

    INTRODUCTION: Hereditary alpha-tryptasemia (HαT) is caused by the increased copy number of TPSAB1 when encoding for alpha-tryptase, resulting in elevated basal serum tryptase (BST). Many affected individuals report irritable bowel syndrome–like and reflux symptoms. We aimed to assess the prevalence of HαT in celiac disease (CeD) and whether this genetic trait modifies disease course. METHODS: This study included a prospective cohort of subjects with CeD or nonceliac gluten sensitivity (NCGS) either at diagnosis (Dx), with persisting symptoms on a gluten-free diet, or in clinical remission. BST levels were determined by immunoassay, and tryptase genotyping was performed on genomic DNA using digital droplet polymerase chain reaction (PCR) [ddPCR]. Duodenal and gastric biopsies were stained for c-KIT, and mast cell (MC) counts were averaged over 5 high power field (hpf). RESULTS: There were 153 eligible subjects: 13 with NCGS and 140 with CeD (8 patients with new Dx, 66 with persisting symptoms, 66 in remission). HαT was found in 9 subjects, all symptomatic with CeD (6.4%). One was new Dx, and the others had persisting symptoms (12.3% of subgroup). Excluding HαT, BST levels were higher among patients with CeD vs NCGS (median 5.4 vs 3.9 mcg/L P < 0.05). Duodenal MC counts were higher in CeD vs controls ( P < 0.05) and 24% higher in those with HαT (median HαT CeD 27.3/hpf, non-HαT CeD 22.0/hpf, controls 18.4/hpf). MC counts did not differ based on villous atrophy or clinical presentation. DISCUSSION: The prevalence of HαT in CeD is similar to the general population; however, all participants with CeD and HαT had ongoing gastrointestinal (GI) symptoms. Evaluation for HαT should be considered in the management of patients with CeD and persisting symptoms.


  • Enhanced Production of Lipid Mediators in Plasma and Activation of DNA Damage Pathways in PBMCs Are Correlated With the Severity of Ancestral SARS ‐ CoV ‐2 Infection

    by Jeffrey A. Tomalka, Anna Owings, Michelle Galeas‐Pena, Carly G. K. Ziegler, Tanya O. Robinson, Thomas G. Wichman, Hannah Laird, Haley B. Williams, Neha S. Ghaliwal, Steven Everman, et al.

    Many questions remain unanswered regarding the implication of genetics and lipid metabolites with severe SARS‐CoV‐2 infections. We performed bulk RNA‐seq and a total fatty acid panel analysis on PBMCs and plasma collected from 10 infected and 10 uninfected patients. Univariate comparison of lipid metabolites using the Mann–Whitney U ‐test revealed that six lipid metabolites were significantly increased in COVID‐19 patients, including the lipid mediators arachidonic acid (AA) and eicosapentaenoic acid (EPA), which both give rise to eicosanoids. Key lipids implicated in inflammation, including AA and EPA, along with the fatty acids DHA and DPA, were significantly and positively correlated to the WHO disease severity score. Analysis of our bulk RNA‐seq dataset demonstrated distinct transcriptional profiles leading to a segregation of COVID‐19 patients based on the WHO score. Ontology, KEGG, and Reactome analysis identified several key pathways and nodes that were enriched for genes related to innate immunity, interactions between lymphoid and nonlymphoid cells, interleukin signaling, and subsequent DNA damage pathways. EPA levels correlated with heightened cell cycling and DNA damage pathways observed in patients with a high WHO score. We studied gene expression in nasopharyngeal swabs from 58 healthy and COVID‐19 participants and identified that genes implicated in eicosanoid synthesis, such as alox5, alox12, and alox15B, were specifically up‐regulated in high WHO score patients in several cell types of the nasopharynx, especially goblet cells across different viral variants (Deta and Omicron). Using published nasal scRNA‐seq datasets from COVID‐19 patients, we evaluated the expression of genes implicated in eicosanoid synthesis, such as ALOX5 , ALOX15, and ALOX15B , across nasal cell types and COVID‐19 severity groups. Altogether, our study highlights the fact that the increase in specific lipids implicated in inflammation and the genes required for their synthesis correlated with the severity of the SARS‐CoV‐2 infection.


  • Open Access

    Activity of Various Cathepsin Proteases and Enrichment of Klotho Protein in the Urine and Urinary Extracellular Vesicles After SARS-CoV-2 Infection

    by Niharika Bala, Ramish H. Rafay, Sarah C. Glover, Abdel A. Alli

    Background: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for causing the Coronavirus disease 2019 (COVID-19) outbreak. While mutations cause the emergence of new variants, the ancestral SARS-CoV-2 strain is unique among other strains. Methods: Various clinical parameters, the activity of cathepsin proteases, and the concentration of various proteins were measured in urine samples from COVID-19-negative participants and COVID-19-positive participants. Urinary extracellular vesicles (uEVs) were isolated from urine samples from the two groups and used for proteomic analysis and subsequent pathway analyses. Results: Activity levels of cathepsin S and L were greater in the urine of COVID-19-positive participants. The concentration of C-reactive protein, transmembrane serine protease 2, and klotho protein were significantly greater in the urine of COVID-19-positive participants. There was a greater amount of uEVs in the COVID-19 group and klotho protein was found to be enriched in uEVs from the COVID-19 group. Pathway analyses of the proteomics data showed most of the identified proteins were involved in signal transduction, stress response, protein metabolism, and transport. The identified proteins were predominantly associated with cellular membranes and with function of the cytoskeleton, enzyme regulation, and signal transduction. Conclusions: Taken together, our data identify novel urinary biomarkers that could be used to further investigate the long-term effects of SARS-CoV-2 infection.


  • Open Access

    An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfection

    by Carly G. K. Ziegler, Anna H. Owings, Michelle Galeas-Pena, Samuel W. Kazer, Vincent N. Miao, Andrew W. Navia, Ying Tang, Joshua D. Bromley, Peter Lotfy, Meredith Sloan, et al.

    Recent case reports and epidemiological data suggest that fungal infections represent an underappreciated complication among people with severe COVID-19. However, the frequency of fungal colonization in patients with COVID-19 and associations with specific immune responses in the airways remain incompletely defined. We previously generated a single-cell RNA-sequencing data set characterizing the upper respiratory microenvironment during COVID-19 and mapped the relationship between disease severity and the local behavior of nasal epithelial cells and infiltrating immune cells. Our previous study, in agreement with findings from related human cohorts, demonstrated that a profound deficiency in host immunity, particularly in type I and type III interferon signaling in the upper respiratory tract, is associated with rapid progression to severe disease and worse clinical outcomes. We have now performed further analysis of this cohort and identified a subset of participants with severe COVID-19 and concurrent detection of Candida species-derived transcripts within samples collected from the nasopharynx and trachea. Here, we present the clinical characteristics of these individuals. Using matched single-cell transcriptomic profiles of these individuals’ respiratory mucosa, we identify epithelial immune signatures suggestive of IL17 stimulation and anti-fungal immunity. Further, we observe a significant expression of anti-fungal inflammatory cascades in the nasal and tracheal epithelium of all participants who went on to develop severe COVID-19, even among participants without detectable genetic material from fungal pathogens. Together, our data suggest that IL17 stimulation—in part driven by Candida colonization—and blunted interferon signaling represent a common feature of severe COVID-19 infection. IMPORTANCE: In this paper, we present an analysis suggesting that symptomatic and asymptomatic fungal coinfections can impact patient disease progression during COVID-19 hospitalization. By looking into the presence of other pathogens and their effect on the host immune response during COVID-19 hospitalizations, we aim to offer insight into an underestimated scenario, furthering our current knowledge of determinants of severity that could be considered for future diagnostic and intervention strategies.


  • Open Access

    Impact of variants and vaccination on nasal immunity across three waves of SARS-CoV-2

    by Jaclyn M. Long, Vincent N. Miao, Anna H. Owings, Ying Tang, Joshua D. Bromley, Samuel W. Kazer, Kyle Kimler, Chelsea Asare, Carly G. K. Ziegler, Samira Ibrahim, et al.

    SARS-CoV-2 infection and COVID-19 disease vary with respect to viral variant and host vaccination status. However, how vaccines, emergent variants, and their intersection shift host responses in the human nasal mucosa remains uncharacterized. We and others have shown during the first SARS-CoV-2 wave that a muted nasal epithelial interferon response at the site of infection underlies severe COVID-19. We sought to further understand how upper airway cell subsets and states associate with COVID-19 phenotypes across viral variants and vaccination. Here, we integrated new single-cell RNA-sequencing (scRNA-seq) data from nasopharyngeal swabs collected from 67 adult participants during the Delta and Omicron waves with data from 45 participants collected during the original (Ancestral) wave in our prior study. By characterizing detailed cellular states during infection, we identified changes in epithelial and immune cells that are both unique and shared across variants and vaccination status. By defining SARS-CoV-2 RNA+ cells for each variant, we found that Delta samples had a marked increase in the abundance of viral RNA+ cells. Despite this dramatic increase in viral RNA+ cells in Delta cases, the nasal cellular compositions of Delta and Omicron exhibit greater similarity, driven partly by myeloid subsets, than the Ancestral landscapes associated with specialized epithelial subsets. We found that vaccination prior to infection was surprisingly associated with nasal macrophage recruitment and activation rather than adaptive immune cell signatures. While patients with severe disease caused by Ancestral or Delta variants had muted interferon responses, Omicron-infected patients had equivalent interferon responses regardless of disease severity. Our study defines the evolution of cellular targets and signatures of disease severity in the upper respiratory tract across SARS-CoV-2 variants, and suggests that intramuscular vaccines shape myeloid responses in the nasal mucosa upon SARS-CoV-2 infection.